



## CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: [secretarial@chandan.co.in](mailto:secretarial@chandan.co.in)

[www.chandandiagnostic.com](http://www.chandandiagnostic.com)

---

**Date: February 14, 2026**

To,  
The Listing Department  
**National Stock Exchange of India Ltd.**  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra- Kurla Complex, Bandra (East),  
Mumbai - 400 051

**Symbol: CHANDAN**  
**ISIN: INE0B2N01016**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Sub: Outcome of Board meeting held on Saturday, February 14, 2026, at 04:00 P.M. (IST)**

Dear Sir/Madam,

In compliance with Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force), this is to inform your good office that the Board of Directors of the Company at their meeting held on Saturday, February 14, 2026, has, inter alia, considered and approved the following items of agenda:-

- (a) Taken on record the Limited Review Report for Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, and
- (b) Taken on record the certificate for utilization of funds issued by the Statutory Auditor of the company.

Further, pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 and our communication letter dated December 30, 2025, the trading window for dealing in securities of the Company had already been closed for Designated Person(s), Connected Person(s) and their immediate relative(s) with effect from January 01, 2026 and shall re-open after the expiry of 48 hours from the aforesaid un-audited Financial Results for the quarter and nine months ended December 31, 2025 generally made available to the public.

The Board meeting commenced at 04:00 PM and concluded at 04:30 P.M.

Kindly take the above information on record. The above information is also available on the Company's website at [www.chandandiagnostic.com](http://www.chandandiagnostic.com).

Thanking you,

Yours sincerely,  
**For Chandan Healthcare Limited**

**Rajeev Kumar Nain**  
**Company Secretary & Compliance Officer**

**Encl.: as above**

**Independent Auditor' Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
Chandan Healthcare Limited,  
Lucknow

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of M/s. *Chandan Healthcare Limited* ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the nine months ended December 31, 2025 and for the period April 1, 2025 to December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10<sup>th</sup> Floor, Unit No. 1033, Sector 62, Noida-201005.

**Branch Office:** -SEJ Plaza – Second Floor, Office No S34, Marve Road, Above N M Medical, Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.

**Branch Office:** - A-504, Ansal Chamber-1, Bhikaji Cama Place, New Delhi-110066.

☎ : CA Saurabh Tyagi: 7718802884, CA Navodit Tyagi: 9167436404, CA Manoj Modi: 9022059201.

✉ : [saurabh@msnt.in](mailto:saurabh@msnt.in), [navodit@msnt.in](mailto:navodit@msnt.in), [manoj@msnt.in](mailto:manoj@msnt.in)

4. The Statement includes the results of the following entities:
  - Chandan Pharmacy Limited.
  - Chandan Diagnostic Limited.
  - Indira Diagnostic Centre & Blood Bank Limited.
  
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard specified under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.
  
6. We have reviewed the interim financial results of **Chandan Pharmacy Limited**, which is included in the Statement. We have not, however, reviewed the interim financial results of the other subsidiaries included in the Statement, namely **Chandan Diagnostic Limited** and **Indira Diagnostic Centre & Blood Bank Limited**. These interim financial results have been reviewed by other auditors, and their reports have been furnished to us by the Management. Our conclusion on the Statement, insofar as it relates to the amounts and disclosures pertaining to these two subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter.

For & On Behalf Of

**For MSNT & ASSOCIATES LLP**  
**Chartered Accountants**  
**Firm Registration No.018542C/C400322**

Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375PQKZJU3813

Place: Noida

Date: 14th Feb,2026



Unaudited Consolidated Statement of Financial Results for the Quarter & Nine Months Ended 31st Dec. 2025

Particulars	Quarter Ended				Nine Months Ended		Year Ended 31st March, 2025
	31st Dec, 2025	30th Sept, 2025	31st Dec, 2024	31st Dec, 2025	31st Dec, 2024		
I. Revenue from operations	Unaudited 6,500.74	Unaudited 6,790.17	Unaudited 5,464.49	Unaudited 20,081.08	Unaudited 16,747.47	Audited 23,012.08	
II. Other income	76.55	84.47	17.12	245.49	51.35	205.14	
III. Total revenue(=I+II)	6,577.29	6,874.64	5,481.61	20,326.57	16,798.82	23,217.22	
IV. Expenses:							
Cost of material consumed	317.68	681.93	326.96	1,681.53	980.88	1,545.88	
Purchase of stock-in-trade	2,936.62	2,803.89	2,371.36	8,544.39	7,114.09	9,498.14	
Change in inventories of finished goods, work-in-progress and stock-in-trade.	(249.46)	(41.37)	(124.91)	(332.22)	(374.73)	(282.32)	
Employee benefits expense.	1,167.56	981.24	971.40	3,130.04	2,914.21	3,886.11	
Finance Costs	128.02	139.98	109.33	407.97	327.99	457.53	
Depreciation and amortisation expense	240.40	246.45	134.97	733.30	404.92	674.48	
Other expenses	1,144.17	949.77	1,030.32	3,043.70	3,090.97	4,230.88	
Total expenses (IV)	5,684.97	5,761.87	4,819.44	17,208.71	14,458.33	20,010.70	
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	892.32	1,112.77	662.16	3,117.86	2,340.49	3,206.52	
VI. Exceptional items *	222.87	-	-	222.87	-	-	
VII. Profit/(loss) before extraordinary items and tax (V-VI)	669.45	1,112.77	662.16	2,894.99	2,340.49	3,206.52	
VIII. Extraordinary items	-	-	-	-	-	-	
IX. Profit/(loss) before tax (VII- VIII)	669.45	1,112.77	662.16	2,894.99	2,340.49	3,206.52	
X. Tax expense of continuing operation:-							
Current tax	208.50	249.25	179.87	707.00	539.60	830.58	
Deferred tax	(42.26)	38.15	19.63	34.01	58.90	24.34	
Tax expense(X)	166.22	287.40	199.50	741.01	598.50	854.92	
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	503.23	825.37	462.66	2,153.98	1,741.99	2,351.60	
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-	-	
XIII. Tax expense of discontinuing operations	-	-	-	-	-	-	
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-	
XV. Share of (profit)/ loss transferred to minority interest	(49.42)	(45.31)	(42.36)	(140.03)	(127.07)	(134.53)	
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)	453.81	780.07	420.31	2,013.95	1,614.92	2,217.07	
XVII. Earnings per equity share:-							
(1) Basic	1.86	3.19	2.10	8.24	8.14	10.78	
(2) Diluted	1.86	3.19	2.10	8.24	8.14	10.78	

\* During the period, consequent to the implementation of the New Labour Codes and the revision in the wage definition, the Group remeasured its defined benefit obligations in accordance with Accounting Standard (AS) 15 – Employee Benefits. The resultant impact attributable to past service has been recognised as past service cost and presented as an Exceptional Item. The Consolidated financial results for the period reflect a loss of ₹222.87 lakhs.

As per our report of even date attached  
 For M/s Msnt & Associates LLP  
 Chartered accountants  
 Firm registration no. :- 048942C/C400322



For & on behalf of the board of directors  
 Chandan Healthcare Limited

Amar singh  
 Managing director  
 Din. :- 01096328  
 Place :- Lucknow  
 Date :- 14th Feb, 2026

Rajeev Nain  
 CFO & Company secretary  
 Place :- 14th Feb, 2026



**Independent Auditor' Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report to,  
The Board of Directors,  
Chandan Healthcare Limited,  
Lucknow

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of M/s. *Chandan Healthcare Limited* ("the Company"), for the nine months ended December 31, 2025, for the period April 1, 2025 to December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting", prescribed under Section 133 the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**Head Office:** - A-40, I-Thum, Tower-B, 10<sup>th</sup> Floor, Unit No. 1033, Sector 62, Noida-201005.  
**Branch Office:** -SEJ Plaza – Second Floor, Office No S34, Marve Road, Above N M Medical, Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.  
**Branch Office:** - A-504, Ansal Chamber-1, Bhikaji Cama Place, New Delhi-110066.  
**CA Saurabh Tyagi:** 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.  
**saurabh@msnt.innavodit@msnt.inmanoj@msnt.in**

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the applicable Accounting Standard prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSNT & ASSOCIATES LLP  
Chartered Accountants  
Firm Registration No.018542C/C400322

Navodit Tyagi

Partner

Membership No.-533375

UDIN No: 26533375HGSUMY6966

Place: Noida

Date: 14th Jan,2026



COMPANY NAME :- Chandan Healthcare Limited  
 CIN :- L85110UP2003PLC193493  
 REGISTERED ADDRESS :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Unaudited Standalone Statement of Financial Results for the Quarter and Nine Month ended 31st Dec, 2025

Particulars	Quarter Ended				Nine Months Ended		Year Ended
	31st Dec, 2025	30th Sept, 2025	31st Dec, 2024	31st Dec, 2025	31st Dec, 2024	31st March, 2025	
I. Revenue from operations	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
II. Other income	3,569.71	3,808.97	2,952.39	11,187.64	9,211.17	12,916.42	
III. Total revenue(=I+II)	67.61	72.55	4.87	212.71	14.61	131.03	
IV. Expenses:	3,637.32	3,881.52	2,957.26	11,400.35	9,225.78	13,047.45	
Cost of material consumed	322.93	676.99	322.88	1,676.91	968.64	1,542.19	
Purchase of stock-in-trade	167.10	132.59	102.30	432.28	306.90	446.61	
Change in inventories of finished goods, work-in-progress and stock-in-trade.	(7.65)	19.13	(3.51)	30.60	(10.53)	(19.18)	
Employee benefits expense.	1,034.94	847.37	833.43	2,729.67	2,500.29	3,338.56	
Finance Costs	93.75	105.90	86.29	305.55	258.88	356.83	
Depreciation and amortisation expense	236.99	240.38	133.56	717.75	400.68	642.24	
Other expenses	1,051.20	877.13	957.76	2,805.46	2,873.27	3,923.66	
Total expenses (IV)	2,899.26	2,899.48	2,432.71	8,698.22	7,298.13	10,230.91	
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)	738.06	982.03	524.55	2,702.13	1,927.65	2,816.54	
VI. Exceptional items *	206.46	-	-	206.46	-	-	
VII. Profit/(loss) before extraordinary items and tax (V-VI)	531.60	982.03	524.55	2,495.67	1,927.65	2,816.54	
VIII. Extraordinary items	-	-	-	-	-	-	
IX. Profit/(loss) before tax (VII- VIII)	531.60	982.03	524.55	2,495.67	1,927.65	2,816.54	
X. Tax expense of continuing operation:-	-	-	-	-	-	-	
Current tax	170.39	218.48	142.06	607.35	426.19	700.14	
Deferred tax	(35.02)	35.48	21.90	35.93	65.70	38.61	
Tax expense(X)	135.37	253.96	163.96	643.28	491.89	738.75	
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)	396.23	728.08	360.59	1,852.39	1,435.76	2,077.79	
XII. Profit/(loss) from discontinuing operations	-	-	-	-	-	-	
XIII. Tax expense of discontinuing operations	-	-	-	-	-	-	
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-	
XV. Share of (profit) loss transferred to minority interest	-	-	-	-	-	-	
XVI. Profit (Loss) after tax attributable to owners of the company (XI+XIV+XV)	396.23	728.08	360.59	1,852.39	1,435.76	2,077.79	
XVII. Earnings per equity share:							
(1) Basic	1.62	2.98	1.80	7.58	7.18	10.10	
(2) Diluted	1.62	2.98	1.80	7.58	7.18	10.10	

\* During the period, pursuant to the implementation of the New Labour Codes and the resultant change in the definition of wages, the Company recognised additional defined benefit obligations based on actuarial valuation in accordance with Accounting Standard (AS) 15 – Employee Benefits. The impact relating to employee service in prior periods has been recognised as past service cost and disclosed as an Exceptional Item. The Standalone financial results for the period reflect a loss of ₹206.46 lakhs.

As per our report of even date attached

For M/s Msmt & Associates, LLP

Chartered accountants  
 Firm registration no. :- 018542CC400322

018542CC400322  
 CHANDAN HEALTHCARE LLP  
 Navodit Singh  
 Partner  
 Membership no. :- 8533375  
 UDIN no. :- 26533375H0000006966  
 Place :- Noida  
 Date :- 14th Feb, 2026

For & on behalf of the board of directors  
 Chandan Healthcare Limited

Amar Singh  
 Managing director  
 Din. :- 01096328  
 Place :- Lucknow  
 Date :- 14th Feb, 2026

Rajeev Nain  
 CFO & Company secretary  
 Place :- 14th Feb, 2026  
 Date :- Lucknow

Asmita Singh  
 Managing director  
 Din. :- 01098055  
 Place :- Lucknow  
 Date :- 14th Feb, 2026



**MSNT** MSNT & ASSOCIATES LLP  
CHARTERED ACCOUNTANTS CHARTERED ACCOUNTANTS

14<sup>th</sup> February, 2026.

To,  
The Manager – Listing Department.  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**Reference: - Chandan Healthcare Limited**

**NSE Code:-CHANDAN**

**ISIN: INE0B2N01016**

**Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations) for the Quarter ended on 31<sup>st</sup> December, 2025.**

Dear Sir,

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on Wednesday, 4 February, 2026.

This is for your information and records please.

Please take the above information on record.

Thanking You,

Yours Faithfully



**Head Office:** - A-40, I-Thum, Tower-B,10<sup>th</sup> Floor, Unit No. 1033, Sector 62, Noida-201005.  
**Branch Office:** -SEJ Plaza – Second Floor, Office No S34, Marve Road, Above N M Medical,  
Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.  
**Branch Office:** - A-504,Ansal Chamber-1, Bhikaji Cama Place, New Delhi-110066.  
**CA Saurabh Tyagi:** 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:**  
9022059201.  
**saurabh@msnt.innavodit@msnt.inmanoj@msnt.in**

**Annexure 1-Statement of Deviation or Variation in Utilization of Funds Raised**

Name of the Listed Entity	Chandan Healthcare Limited
Mode of Raising Fund	Initial Public Offer
Date of raising Fund	17th Feb, 2025
Amount Raised (Rs. in Lakhs)	7044.64
Report filed for the quarter/half year	31 <sup>ST</sup> December, 2025
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation/Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If yes, Date of shareholder approval	--
Explanation for Deviation/Variation	--
Comments of the Audit Committee after review	
Comments of the Auditors, if any	

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation (Amount in Lakhs)	Modified Allocation, if any	Funds Utilised till 31.12.2025	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
				(Amount in Lakhs)		
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ashiyana, Lucknow, Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.11	0	710.11	0	
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Ayodhya , Uttar Pradesh.</i>						
Funding capital expenditure towards installation of plant & machinery in our New premises along with required, electric and fabrication work	NO	710.23	0	710.23	0	
<i>Funding capital expenditure requirements for setting up of a flagship diagnostic centre in Jankipuram , Lucknow, Uttar Pradesh.</i>						



Funding capital expenditure towards installation of plant & machinery in our New premises along with required civil, electric and fabrication work	NO	3281.58	0	973.54	0	Partially Utilised till December, 2025
General corporate purposes	NO	1672.45	0	1672.45	0	
Issue related expenses	NO	670.27	0	670.27	0	

**Deviation or variation could mean:**

Deviation in the Objects or purposes for which the funds have been raised or

Deviation in the amount of funds actually utilized as against what was originally disclosed or

Change in terms of a contract referred to in the funds raising documents I.e., prospectus, Letter of Offer

**For MSNT & ASSOCIATES LLP**

**Chartered Accountants**

**Firm Registration No.018542C/C400322**

**Navodit Tyagi**

**Partner**

**Membership No.-533375**

**UDIN No: 26533375GOJSTS5951**

**Place: Noida**

**Date: 14/02/2026**

